Software innovations for patient-specific theranostics and molecular radiotherapy

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

advertisement
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

Bracco Imaging to acquire Blue Earth Diagnostics for $450 million Will gain rights over Axumin

MiE showcases cardiac PET scanner, Ancoris, at SNMMI Provides simultaneous 3D cardiac PET perfusion and CFR

First dual PET isotope scans performed on living organism Discussed at SNMMI 2019 Annual Meeting

Siemens showcases works in progress at SNMMI Includes TeamPlay, syngo Virtual Cockpit and a number of AI algorithms

Philips shares insights on PET/CT utilization trends at SNMMI Continued growth in use expected through 2019

Theranostics continue to gain momentum Investments ramp up but challenges remain

GE debuts Discovery IQ Gen 2 PET/CT system at SNMMI Equipped with MotionFree to prevent blurring of images

Rethinking training and education for the future of medicine at SNMMI Discussing innovations and efforts of SNMMI Technologist Section

SNMMI Product Showcase Don't miss these solutions on the exhibit floor

Mobile PET relieves hardship for rural cancer patients Mobile PET isn't just good medicine, it's good business

Software innovations for patient-specific theranostics and molecular radiotherapy

By Sébastien Vauclin

Molecular radiotherapy (MRT) is a promising and quickly expanding set of therapeutic options for treating many cancer cases, including cases where conventional techniques are unsuccessful. Cancer cases have been treated with radiopharmaceuticals since the 1940s, but the number and range of radiotherapeutics on the market have recently expanded significantly.

To help optimizing radionuclides-based therapies in clinical routine, software and digital technologies are expected to play an innovative and primary role in the future. In parallel with their tremendous contribution over the past 20 years to the external beam radiation therapy (EBRT) domain, software technologies bear the same promise for MRT: image-based, 3D voxel-level precision, patient-specific adaptive treatment planning, in vivo dose control, etc. These well-known features and corresponding benefits in EBRT are fairly new to the MRT world and will become de facto standards of practice within the next few years.
Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED


The even more recent software technologies, also called digital technologies, have an even bigger potential impact and benefit for the prognosis, improvement and personalization of cancer therapies. Indeed, the next challenge is to go from protocol-based treatments “one size fits all”, to fully personalized diagnosis, prognosis, treatment planning and patient follow-up. A given patient being nowadays characterized by more than 10,000 descriptors, only software and data-driven machine processing can fully take into account such complexity.

Cancer diagnostics, treatment planning and patient follow-up in molecular radiotherapy
Nuclear medicine has the intrinsic potential of allowing pre- and post-therapeutic in vivo bio distribution studies. Molecular radiotherapy, which involves the metabolic vectorization of radioactive products within tumors and their selective destruction, is an alternative suggested in an increasing number of cancer treatment centers worldwide.

However, the increment of radionuclide therapy applications has brought the attention of both the scientific community and the institutional bodies to the need for personalized planning and verification of the absorbed dose delivered to individual patients, as is currently standard practice in external beam radiotherapy (EBRT).

It represents a challenge, especially, for radionuclide treatments given systemically, whose bio distribution and ultimate targeting is greatly heterogeneous among individuals and whose therapeutic effect is exerted over a long period of time (days or weeks in many cases, depending on both biological and physical properties of the radiopharmaceuticals).

  Pages: 1 - 2 - 3 >>

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment